Levofloxacin in the treatment of nosocomial infection in critically ill patients;Levofloxacino en el tratamiento de infecciones nosocomiales en pacientes críticos

Revista Espanola de Quimioterapia

Volumn 21, Issue 2, 2008, Pages 83-92

  Álvarez Lerma, Francisco ^a   Romero Lujan J L ^b   Moron Jimenez A ^c   Ortiz Lopez R ^d   Borges Sa M ^e   Grau Cerrato, S ^a   Gracia Arnillas, M P ^a  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HÔPITAL DU BOCAGE   (France)

^e HOSPITAL SON LLÀTZER   (Spain)

Author keywords

Critical patients; ICU; Levofloxacin; Nosocomial infections

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTRIAXONE; LEVOFLOXACIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ADULT; AGITATION; ANAPHYLACTIC SHOCK; APACHE; ARTICLE; BACTEREMIA; CATHETER INFECTION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CRITICALLY ILL PATIENT; DEMOGRAPHY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG UTILIZATION; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LEUKOPENIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MECHANICAL VENTILATION ASSOCIATED PNEUMONIA; MORTALITY; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; PHLEBITIS; PHOTOTOXICITY; PNEUMONIA; RASH; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SURGICAL INFECTION; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URETHRAL CATHETER; URINARY TRACT INFECTION; VOMITING;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; CROSS INFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; RETROSPECTIVE STUDIES;

EID: 47649098746     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
2. Hurst M, Lamb HM, Scott LJ, Figgitt DP. Levofloxacin: a review of use in the treatment of bacterial infections. Drugs 2002;62:2127-67.
3. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998;30:397-404.
4. File Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficay and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72.
5. Shah PM, Maesen FP, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double blind study. J Antimicrob Chemother 1999;43:529-39.
6. Tarshis GA, Miskin BM, Jones TM, Champlin J, Wingert KJ, Breen JD, et al. Once-daily oral gatifloxacin versus oral levofloxacin in the treatment of uncomplicated skin and soft tissue infections: double blind, multicenter, randomized study. Antimicrob Agents Chemother 2001;45:2358-62.
7. Klimberg IW, Cox II CE, Fowler CL, King W, Kim SS, Callery-D'Amico S. A controlled trial o levofloxacin and lemofloxacin in the treatment of complicated urinary tract infection. Urology 1998;51:610-5.
8. Jones RN, Croco MA, Pfaller MA, Beach ML, Kugler KC, and SENTRY antimicrobial surveillance programs participans (the Americas). Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997). Clin Microbiol Infect 1999;5:540-6.
9. Gesu GP, Marchetti F, Piccoli L, Cavallero A. Levofloxacin and Ciprofloxacin in vitro activities against 4.003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 2003;47:816-9.
10. Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn Microb Infect Dis 2003;46:131-7.
11. Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F, Stefani S. Levofloxacin in vitro activity and time-kill evaluation on Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother 2000;45:115-7.
12. Álvarez Lerma F, Palomar M, Olaechea P, León C, Sánchez M, Bermejo B y Grupo de Estudio de Levofloxacino en UCI. Estudio observacional sobre el uso de levofloxacino en pacientes ingresados en UCI. Enferm Infecc Microbiol Clin 2004;22:216-22.
13. Álvarez Lerma F, Palomar M, Olaechea P, León C, Sánchez M, Bermejo B y Grupo de Estudio de Levofloxacino en UCI. Levofloxacino en pacientes ingresados en UCI. Factores que influyen en la elección de la dosis y en su uso en terapia combinada. Rev Esp Quimioter 2004;17:57-63.
14. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
15. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Disease Society of America/American Thoracic Society Consensus Guidelines on the Management of Community Acquired Pneumonia in Adults. Clin Infect Dis 2007; 44:S27-72.
16. Álvarez Rocha L, Alos JI, Blanquer J, Álvarez-Lerma F, Garau J, Guerrero A, et al. Guias para el manejo de la neumonia comunitaria del adulto que precisa ingreso en el hospital. Med Intensive 2005;29:21-62.
17. Schmitz FJ, Verhoef J, Fluit AC. Comparative activities of six different fluoroquinolones against 9.682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. Int J Antimicrob Agents 1999;12:311-31.
18. Montanari MP, Mingoia M, Marchetti F, Varaldo PE. In vitro activity of levofloxacin against gram-positive bacteria. Chemotherapy 1999;45:411-7.
19. Grupo de Trabajo de Enfermedades Infecciosas de la Sociedad Española de Medicina Intensiva y Unidades Coronarias (GTEI-SEMICYUC). Estudio Nacional de Vigilancia de Infección Nosocomial en UCI. Informe del año 2006.
20. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279:125-9.
21. Wright DH, Brown GH, Peterson ML, Rodtschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000;46:669-83.
22. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001;119:1114-22.
23. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Shentang JJ. Pharmacodynamics of intravenous ciprofloxacin in serious ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
24. Drusano GL, Jonson DE, Rosen M, Standifor HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-90.
25. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005;41:118-21.
26. Thornsberry C, Sahm DF, Kelly LJ, Critchley IA. Jones ME, Evangelista A, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Clin Infect Dis 2002;34(Suppl. 1):4-17.
27. Paladino JA, Sunderlin JL, Forrest A, Schentag JJ. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or resistant Pseudomonas aeruginosa. J Antimicro Chemother 2003;52:457-63.
28. Khan JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001;47(Suppl. 3):32-7.